Sp779
THE CONTRIBUTION OF HIF-2A DURING OBESITY TO HEPATIC STEATOSIS
Date
May 20, 2024
Presenter
University of Michigan
Tracks
Related Products
The Tumor Microenvironment Across GI Cancers
The tumor microenvironment (TME) is a hallmark of solid tumor cancers. In this session we will explore the TME of colon and pancreatic cancer, including its major components, its role in pathogenesis and therapy resistance, and ongoing efforts to target the TME…
COMPARATIVE ANALYSIS OF GENE EXPRESSION PROFILES OF ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS BASED ON ANATOMICAL CLASSIFICATION
BACKGROUND: Siewert's topographic classification (SW) has been used for treatment plan of esophagogastric junction adenocarcinomas (EGJA). But recently, molecular classifications categorized EGJA with similar characteristics and prognosis…
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
